• Cleo L. Crunelle
  • Wim van den Brink
  • Franz Moggi
  • Maija Konstenius
  • Johan Franck
  • Frances R. Levin
  • Geurt van de Glind
  • Zsolt Demetrovics
  • Corne Coetzee
  • Mathias Luderer
  • Arnt Schellekens
  • Frieda Matthys

Adult attention deficit/hyperactivity disorder (ADHD) often co-occurs with substance use disorders (SUD) and is associated with early onset and more severe development of SUD and with reduced treatment effectiveness. Screening tools allow for a good recognition of possible ADHD in adults with SUD and should be used routinely, followed by an ADHD diagnostic process initiated as soon as possible. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended-release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. This paper includes evidence- and consensus-based recommendations developed to provide guidance in the screening, diagnosis and treatment of patients with ADHD-SUD comorbidity.

Original languageEnglish
Pages (from-to)43-51
JournalEuropean Addiction Research
Issue number1
Publication statusPublished - 2018

    Research areas

  • Attention deficit/hyperactivity disorder, Substance use disorders, Diagnosis, Treatment, Consensus

ID: 46824446